Markt geschlossen -
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
13.85 USD | -5.65% | -10.99% | -58.95% |
Voraussichtliche Gewinn- und Verlustrechnung: Pacira BioSciences, Inc.
Steuerjahr: Dezember | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Umsatz 1 | 421 | 429.6 | 541.5 | 666.8 | 675 | 692.8 | 653.9 | 663.3 |
Veränderung | - | 2.05% | 26.04% | 23.14% | 1.22% | 2.64% | -5.62% | 1.44% |
EBITDA 1 | 94.86 | 112.6 | 204 | 212.7 | 214.5 | 214.1 | 211.7 | 264 |
Veränderung | - | 18.68% | 81.21% | 4.29% | 0.82% | -0.17% | -1.11% | 24.68% |
Betriebsergebnis (EBIT) 1 | 75.28 | 99.3 | 189.2 | 194.8 | 197.7 | 180.5 | 168 | 212.2 |
Veränderung | - | 31.9% | 90.55% | 2.94% | 1.48% | -8.66% | -6.94% | 26.32% |
Gezahlte Zinsen 1 | -23.63 | -25.67 | -31.75 | -39.98 | -20.31 | -5.54 | -8.469 | -4.844 |
Gewinn vor Steuern (EBT) 1 | -10.75 | 20.09 | 56.4 | 13.3 | 61.7 | 149.1 | 129.3 | 309.9 |
Veränderung | - | - | 180.77% | -76.42% | 363.85% | 141.62% | -13.25% | 139.64% |
Nettoergebnis 1 | -11.02 | 145.5 | 41.98 | 15.91 | 41.96 | 72.61 | 36.21 | 73 |
Veränderung | - | - | -71.15% | -62.1% | 163.72% | 73.07% | -50.13% | 101.61% |
Datum der Veröffentlichung | 20.02.20 | 25.02.21 | 24.02.22 | 28.02.23 | 29.02.24 | - | - | - |
Vorläufige Bilanz: Pacira BioSciences, Inc.
Steuerjahr: Dezember | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Nettoverschuldung 1 | 228 | 363 | 464 | 585 | 244 | 125 | -32.2 | -243 |
Veränderung | - | 59.21% | 27.82% | 26.08% | -58.29% | -48.74% | -125.76% | -854.66% |
Datum der Veröffentlichung | 20.02.20 | 25.02.21 | 24.02.22 | 28.02.23 | 29.02.24 | - | - | - |
Prognostizierter Cashflow: Pacira BioSciences, Inc.
Steuerjahr: Dezember | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
CAPEX Investitionsaufwand 1 | 10.16 | 37.8 | 45.87 | 30.08 | 15.16 | 20.97 | 11.76 | 12.4 |
Veränderung | - | 272.09% | 21.34% | -34.43% | -49.59% | 38.29% | -43.89% | 5.4% |
Free Cashflow (FCF) 1 | 69.5 | 73.03 | 79.85 | 115.2 | 139.5 | 155.2 | 165.9 | 160.6 |
Veränderung | - | 5.07% | 9.35% | 44.27% | 21.09% | 11.25% | 6.89% | -3.15% |
Datum der Veröffentlichung | 20.02.20 | 25.02.21 | 24.02.22 | 28.02.23 | 29.02.24 | - | - | - |
Voraussichtliche Finanzkennzahlen: Pacira BioSciences, Inc.
Steuerjahr: Dezember | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Rentabilität | ||||||||
EBITDA-Marge (%) | 22.53% | 26.2% | 37.67% | 31.9% | 31.78% | 30.91% | 32.38% | 39.8% |
EBIT-Marge (%) | 17.88% | 23.11% | 34.94% | 29.21% | 29.28% | 26.06% | 25.69% | 32% |
EBT-Marge (%) | -2.55% | 4.68% | 10.42% | 1.99% | 9.14% | 21.52% | 19.78% | 46.72% |
Nettogewinn (%) | -2.62% | 33.87% | 7.75% | 2.39% | 6.22% | 10.48% | 5.54% | 11.01% |
FCF-Marge N (%) | 16.51% | 17% | 14.75% | 17.28% | 20.67% | 22.4% | 25.37% | 24.22% |
FCF / Nettogewinn (%) | -630.91% | 50.18% | 190.21% | 724.11% | 332.47% | 213.71% | 458.11% | 220.07% |
Rentabilität | ||||||||
ROA | 9.3% | 9.17% | 8.16% | 6.43% | - | 6.07% | 2.56% | 2.59% |
ROE | 20.91% | 19.82% | 20.25% | 16.04% | - | 11.12% | 4.52% | 4.46% |
Finanzielle Gesundheit | ||||||||
Verschuldungsgrad (Verbindlichkeiten/EBITDA) | 2.4x | 3.22x | 2.27x | 2.75x | 1.14x | 0.58x | - | - |
Verschuldung / Free Cashflow | 3.28x | 4.97x | 5.81x | 5.08x | 1.75x | 0.8x | - | - |
Kapitalintensität | ||||||||
CAPEX / Umsatz (%) | 2.41% | 8.8% | 8.47% | 4.51% | 2.25% | 3.03% | 1.8% | 1.87% |
CAPEX / EBITDA (%) | 10.71% | 33.58% | 22.48% | 14.14% | 7.07% | 9.79% | 5.56% | 4.7% |
CAPEX / FCF (%) | 14.62% | 51.76% | 57.44% | 26.11% | 10.87% | 13.51% | 7.09% | 7.72% |
Elemente pro Aktie | ||||||||
Cashflow pro Aktie 1 | - | - | - | - | - | - | - | - |
Veränderung | - | - | - | - | - | - | - | - |
Dividende pro Aktie 1 | - | - | - | - | - | - | - | - |
Veränderung | - | - | - | - | - | - | - | - |
Buchwert je Aktie 1 | 8.47 | 14.2 | 16.33 | 16.87 | - | 18.39 | 20.41 | 20.62 |
Veränderung | - | 67.67% | 14.98% | 3.35% | - | - | 10.97% | 1% |
Gewinn pro Aktie 1 | -0.27 | 3.33 | 0.92 | 0.34 | 0.89 | 1.26 | 1.43 | 3.145 |
Veränderung | - | -1’333.33% | -72.37% | -63.04% | 161.76% | 41.57% | 13.49% | 119.93% |
Anz. der Aktien (in Tausend) | 41’731 | 43’444 | 44’544 | 45’882 | 46’438 | 46’127 | 46’127 | 46’127 |
Datum der Veröffentlichung | 20.02.20 | 25.02.21 | 24.02.22 | 28.02.23 | 29.02.24 | - | - | - |
2024 * | 2025 * | |
---|---|---|
KGV | 11x | 9.69x |
KBV | 0.75x | 0.68x |
EV / Sales | 1.1x | 0.93x |
Rendite | - | - |
Gewinn pro Aktie & Dividende
Historische Entwicklung KGV
- Börse
- Aktien
- A1H68T Aktie
- Finanzen Pacira BioSciences, Inc.
MarketScreener is also available in this country: United States.
Switch edition